Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220920
Max Phase: Preclinical
Molecular Formula: C19H20N6O2
Molecular Weight: 364.41
Associated Items:
ID: ALA5220920
Max Phase: Preclinical
Molecular Formula: C19H20N6O2
Molecular Weight: 364.41
Associated Items:
Canonical SMILES: COc1cccc2cc(-c3nn(C4CCOCC4)c4ncnc(N)c34)[nH]c12
Standard InChI: InChI=1S/C19H20N6O2/c1-26-14-4-2-3-11-9-13(23-16(11)14)17-15-18(20)21-10-22-19(15)25(24-17)12-5-7-27-8-6-12/h2-4,9-10,12,23H,5-8H2,1H3,(H2,20,21,22)
Standard InChI Key: ZEKMMWTXUQTYFE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 364.41 | Molecular Weight (Monoisotopic): 364.1648 | AlogP: 2.92 | #Rotatable Bonds: 3 |
Polar Surface Area: 103.87 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.61 | CX Basic pKa: 3.66 | CX LogP: 1.48 | CX LogD: 1.48 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.58 | Np Likeness Score: -0.84 |
1. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K.. (2022) Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021)., 238 [PMID:35688004] [10.1016/j.ejmech.2022.114498] |
Source(1):